Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer

Angela Collarino, Lenka M. Pereira Arias-Bouda, Renato A. Valdés Olmos, Pieternel van der Tol, Petra Dibbets-Schneider, Lioe Fee de Geus-Oei, Floris H.P. van Velden (Corresponding Author)

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)

Abstract

Purpose: Recent developments in iterative image reconstruction enable absolute quantification of SPECT/CT studies by incorporating compensation for collimator-detector response, attenuation, and scatter as well as resolution recovery into the reconstruction process (Evolution; Q.Metrix package; GE Healthcare, Little Chalfont, UK). The aim of this experimental study is to assess its quantitative accuracy for potential clinical 99mTc-sestamibi (MIBI)-related SPECT/CT application in neoadjuvant chemotherapy response studies in breast cancer. Methods: Two phantoms were filled with MIBI and acquired on a SPECT/CT gamma camera (Discovery 670 Pro; GE Healthcare), that is, a water cylinder and a NEMA body phantom containing six spheres that were filled with an activity concentration reflecting clinical MIBI uptake. Subsequently, volumes-of-interest (VOI) of each sphere were drawn (semi)automatically on SPECT using various isocontour methods or manually on CT. Finally, prone MIBI SPECT/CT scans were acquired 5 and 90 min p.i. in a locally advanced breast cancer patient. Results: Activity concentration in the four largest spheres converged after nine iterations of evolution. Depending on the count statistics, the accuracy of the reconstructed activity concentration varied between -4.7 and -0.16% (VOI covering the entire phantom) and from 6.9% to 10% (8.8 cm Ø cylinder VOI placed in the center of the phantom). Recovery coefficients of SUVmax were 1.89 ± 0.18, 1.76 ± 0.17, 2.00 ± 0.38, 1.89 ± 0.35, and 0.90 ± 0.26 for spheres with 37, 28, 22, 17, and 13 mm Ø, respectively. Recovery coefficients of SUVmean were 1.07 ± 0.06, 1.03 ± 0.09, 1.17 ± 0.21, 1.10 ± 0.20, and 0.52 ± 0.14 (42% isocontour); 1.10 ± 0.07, 1.02 ± 0.09, 1.13 ± 0.19, 1.06 ± 0.19, and 0.51 ± 0.13 (36% isocontour with local background correction); and 0.96, 1.09, 1.03, 1.03, and 0.29 (CT). Patient study results were concordant with the phantom validation. Conclusions: Absolute SPECT/CT quantification of breast studies using MIBI seems feasible (<17% deviation) when a 42% isocontour is used for delineation for tumors of at least 17 mm diameter. However, with tumor shrinkage, response evaluation should be handled with caution, especially when using SUVmax.

Original languageEnglish
Pages (from-to)2143-2153
Number of pages11
JournalMedical physics
Volume45
Issue number5
DOIs
Publication statusPublished - May 2018

Fingerprint

Breast Neoplasms
Delivery of Health Care
Technetium Tc 99m Sestamibi
Gamma Cameras
Computer-Assisted Image Processing
Single-Photon Emission-Computed Tomography
Neoplasms
Breast
Single Photon Emission Computed Tomography Computed Tomography
Drug Therapy
Water

Keywords

  • UT-Hybrid-D
  • Breast cancer
  • Resolution modeling
  • SPECT/CT
  • SUV
  • Absolute quantification

Cite this

Collarino, A., Pereira Arias-Bouda, L. M., Valdés Olmos, R. A., van der Tol, P., Dibbets-Schneider, P., de Geus-Oei, L. F., & van Velden, F. H. P. (2018). Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer. Medical physics, 45(5), 2143-2153. https://doi.org/10.1002/mp.12880
Collarino, Angela ; Pereira Arias-Bouda, Lenka M. ; Valdés Olmos, Renato A. ; van der Tol, Pieternel ; Dibbets-Schneider, Petra ; de Geus-Oei, Lioe Fee ; van Velden, Floris H.P. / Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer. In: Medical physics. 2018 ; Vol. 45, No. 5. pp. 2143-2153.
@article{660304e8cbba4a6d9af153254c418d46,
title = "Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer",
abstract = "Purpose: Recent developments in iterative image reconstruction enable absolute quantification of SPECT/CT studies by incorporating compensation for collimator-detector response, attenuation, and scatter as well as resolution recovery into the reconstruction process (Evolution; Q.Metrix package; GE Healthcare, Little Chalfont, UK). The aim of this experimental study is to assess its quantitative accuracy for potential clinical 99mTc-sestamibi (MIBI)-related SPECT/CT application in neoadjuvant chemotherapy response studies in breast cancer. Methods: Two phantoms were filled with MIBI and acquired on a SPECT/CT gamma camera (Discovery 670 Pro; GE Healthcare), that is, a water cylinder and a NEMA body phantom containing six spheres that were filled with an activity concentration reflecting clinical MIBI uptake. Subsequently, volumes-of-interest (VOI) of each sphere were drawn (semi)automatically on SPECT using various isocontour methods or manually on CT. Finally, prone MIBI SPECT/CT scans were acquired 5 and 90 min p.i. in a locally advanced breast cancer patient. Results: Activity concentration in the four largest spheres converged after nine iterations of evolution. Depending on the count statistics, the accuracy of the reconstructed activity concentration varied between -4.7 and -0.16{\%} (VOI covering the entire phantom) and from 6.9{\%} to 10{\%} (8.8 cm {\O} cylinder VOI placed in the center of the phantom). Recovery coefficients of SUVmax were 1.89 ± 0.18, 1.76 ± 0.17, 2.00 ± 0.38, 1.89 ± 0.35, and 0.90 ± 0.26 for spheres with 37, 28, 22, 17, and 13 mm {\O}, respectively. Recovery coefficients of SUVmean were 1.07 ± 0.06, 1.03 ± 0.09, 1.17 ± 0.21, 1.10 ± 0.20, and 0.52 ± 0.14 (42{\%} isocontour); 1.10 ± 0.07, 1.02 ± 0.09, 1.13 ± 0.19, 1.06 ± 0.19, and 0.51 ± 0.13 (36{\%} isocontour with local background correction); and 0.96, 1.09, 1.03, 1.03, and 0.29 (CT). Patient study results were concordant with the phantom validation. Conclusions: Absolute SPECT/CT quantification of breast studies using MIBI seems feasible (<17{\%} deviation) when a 42{\%} isocontour is used for delineation for tumors of at least 17 mm diameter. However, with tumor shrinkage, response evaluation should be handled with caution, especially when using SUVmax.",
keywords = "UT-Hybrid-D, Breast cancer, Resolution modeling, SPECT/CT, SUV, Absolute quantification",
author = "Angela Collarino and {Pereira Arias-Bouda}, {Lenka M.} and {Vald{\'e}s Olmos}, {Renato A.} and {van der Tol}, Pieternel and Petra Dibbets-Schneider and {de Geus-Oei}, {Lioe Fee} and {van Velden}, {Floris H.P.}",
note = "Wiley deal",
year = "2018",
month = "5",
doi = "10.1002/mp.12880",
language = "English",
volume = "45",
pages = "2143--2153",
journal = "Medical physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "5",

}

Collarino, A, Pereira Arias-Bouda, LM, Valdés Olmos, RA, van der Tol, P, Dibbets-Schneider, P, de Geus-Oei, LF & van Velden, FHP 2018, 'Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer' Medical physics, vol. 45, no. 5, pp. 2143-2153. https://doi.org/10.1002/mp.12880

Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer. / Collarino, Angela; Pereira Arias-Bouda, Lenka M.; Valdés Olmos, Renato A.; van der Tol, Pieternel; Dibbets-Schneider, Petra; de Geus-Oei, Lioe Fee; van Velden, Floris H.P. (Corresponding Author).

In: Medical physics, Vol. 45, No. 5, 05.2018, p. 2143-2153.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer

AU - Collarino, Angela

AU - Pereira Arias-Bouda, Lenka M.

AU - Valdés Olmos, Renato A.

AU - van der Tol, Pieternel

AU - Dibbets-Schneider, Petra

AU - de Geus-Oei, Lioe Fee

AU - van Velden, Floris H.P.

N1 - Wiley deal

PY - 2018/5

Y1 - 2018/5

N2 - Purpose: Recent developments in iterative image reconstruction enable absolute quantification of SPECT/CT studies by incorporating compensation for collimator-detector response, attenuation, and scatter as well as resolution recovery into the reconstruction process (Evolution; Q.Metrix package; GE Healthcare, Little Chalfont, UK). The aim of this experimental study is to assess its quantitative accuracy for potential clinical 99mTc-sestamibi (MIBI)-related SPECT/CT application in neoadjuvant chemotherapy response studies in breast cancer. Methods: Two phantoms were filled with MIBI and acquired on a SPECT/CT gamma camera (Discovery 670 Pro; GE Healthcare), that is, a water cylinder and a NEMA body phantom containing six spheres that were filled with an activity concentration reflecting clinical MIBI uptake. Subsequently, volumes-of-interest (VOI) of each sphere were drawn (semi)automatically on SPECT using various isocontour methods or manually on CT. Finally, prone MIBI SPECT/CT scans were acquired 5 and 90 min p.i. in a locally advanced breast cancer patient. Results: Activity concentration in the four largest spheres converged after nine iterations of evolution. Depending on the count statistics, the accuracy of the reconstructed activity concentration varied between -4.7 and -0.16% (VOI covering the entire phantom) and from 6.9% to 10% (8.8 cm Ø cylinder VOI placed in the center of the phantom). Recovery coefficients of SUVmax were 1.89 ± 0.18, 1.76 ± 0.17, 2.00 ± 0.38, 1.89 ± 0.35, and 0.90 ± 0.26 for spheres with 37, 28, 22, 17, and 13 mm Ø, respectively. Recovery coefficients of SUVmean were 1.07 ± 0.06, 1.03 ± 0.09, 1.17 ± 0.21, 1.10 ± 0.20, and 0.52 ± 0.14 (42% isocontour); 1.10 ± 0.07, 1.02 ± 0.09, 1.13 ± 0.19, 1.06 ± 0.19, and 0.51 ± 0.13 (36% isocontour with local background correction); and 0.96, 1.09, 1.03, 1.03, and 0.29 (CT). Patient study results were concordant with the phantom validation. Conclusions: Absolute SPECT/CT quantification of breast studies using MIBI seems feasible (<17% deviation) when a 42% isocontour is used for delineation for tumors of at least 17 mm diameter. However, with tumor shrinkage, response evaluation should be handled with caution, especially when using SUVmax.

AB - Purpose: Recent developments in iterative image reconstruction enable absolute quantification of SPECT/CT studies by incorporating compensation for collimator-detector response, attenuation, and scatter as well as resolution recovery into the reconstruction process (Evolution; Q.Metrix package; GE Healthcare, Little Chalfont, UK). The aim of this experimental study is to assess its quantitative accuracy for potential clinical 99mTc-sestamibi (MIBI)-related SPECT/CT application in neoadjuvant chemotherapy response studies in breast cancer. Methods: Two phantoms were filled with MIBI and acquired on a SPECT/CT gamma camera (Discovery 670 Pro; GE Healthcare), that is, a water cylinder and a NEMA body phantom containing six spheres that were filled with an activity concentration reflecting clinical MIBI uptake. Subsequently, volumes-of-interest (VOI) of each sphere were drawn (semi)automatically on SPECT using various isocontour methods or manually on CT. Finally, prone MIBI SPECT/CT scans were acquired 5 and 90 min p.i. in a locally advanced breast cancer patient. Results: Activity concentration in the four largest spheres converged after nine iterations of evolution. Depending on the count statistics, the accuracy of the reconstructed activity concentration varied between -4.7 and -0.16% (VOI covering the entire phantom) and from 6.9% to 10% (8.8 cm Ø cylinder VOI placed in the center of the phantom). Recovery coefficients of SUVmax were 1.89 ± 0.18, 1.76 ± 0.17, 2.00 ± 0.38, 1.89 ± 0.35, and 0.90 ± 0.26 for spheres with 37, 28, 22, 17, and 13 mm Ø, respectively. Recovery coefficients of SUVmean were 1.07 ± 0.06, 1.03 ± 0.09, 1.17 ± 0.21, 1.10 ± 0.20, and 0.52 ± 0.14 (42% isocontour); 1.10 ± 0.07, 1.02 ± 0.09, 1.13 ± 0.19, 1.06 ± 0.19, and 0.51 ± 0.13 (36% isocontour with local background correction); and 0.96, 1.09, 1.03, 1.03, and 0.29 (CT). Patient study results were concordant with the phantom validation. Conclusions: Absolute SPECT/CT quantification of breast studies using MIBI seems feasible (<17% deviation) when a 42% isocontour is used for delineation for tumors of at least 17 mm diameter. However, with tumor shrinkage, response evaluation should be handled with caution, especially when using SUVmax.

KW - UT-Hybrid-D

KW - Breast cancer

KW - Resolution modeling

KW - SPECT/CT

KW - SUV

KW - Absolute quantification

UR - http://www.scopus.com/inward/record.url?scp=85045037554&partnerID=8YFLogxK

U2 - 10.1002/mp.12880

DO - 10.1002/mp.12880

M3 - Article

VL - 45

SP - 2143

EP - 2153

JO - Medical physics

JF - Medical physics

SN - 0094-2405

IS - 5

ER -

Collarino A, Pereira Arias-Bouda LM, Valdés Olmos RA, van der Tol P, Dibbets-Schneider P, de Geus-Oei LF et al. Experimental validation of absolute SPECT/CT quantification for response monitoring in breast cancer. Medical physics. 2018 May;45(5):2143-2153. https://doi.org/10.1002/mp.12880